# A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Source: https://onco.cc/trials/nct06174987/  
OnCo record `nct06174987` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab deruxtecan in metastatic cancer, run by Daiichi Sankyo, now recruiting.

## Summary

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) is a phase 3 interventional study registered as NCT06174987 by Daiichi Sankyo, with 50 participants planned, started 2024-01-05 and due to reach its primary completion in 2026-08-03. Interventions recorded: T-DXd. Conditions listed: Advanced Cancer, Metastatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06174987
- Phase: 3
- Setting: A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
- Sponsor: Daiichi Sankyo
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06174987: https://clinicaltrials.gov/study/NCT06174987

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct06174987.json